Blood Biomarker to Help Spot Lung Cancer

With help of a blood biomarker, doctors may very soon be able to detect lung cancer early in its stage.

A new study has shown that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer.

Report Suggests Nearly 1 in 3 UK Lung Cancer Patients Die Within 3 Months of Diagnosis
A new study suggests that almost 1 in 3 patients with lung cancer dies within three months of diagnosis in the UK.

Researchers at Cleveland Clinic studied the blood serum of 284 subjects, 48 percent of whom were female with a mean age of 68 years. The subjects were diagnosed with adenocarcinoma or squamous lung cancer: 44 percent of those at stage I, 17 percent at stage II, and 39 percent at stage III. A control group of 194 patients-who matched the cancer patients in age, gender, smoking history, COPD, diabetes, and blood lipids were at risk for lung cancer but did not have the disease. There were 534 metabolites identified, with the concentration of 149 metabolites differing significantly between the cancer and control groups.

Peter J. Mazzone, MD, FCCP, Director of the Lung Cancer Program for the Respiratory Institute at Cleveland Clinic said that the study results showed that patients with lung cancer had altered metabolic processes. This information could lead to the development of a diagnostic biomarker for early detection of lung cancer.

The study abstract has been released in an online supplement of the journal CHEST.

Lung Cancer can Lie Dormant for Two Decades, Says Study
Lung cancers can lie dormant for over 20 years before suddenly turning into an aggressive form of the disease, a new study has suggested.

Source-ANI

Pemetrexed or Docetaxel With Cisplatin Achieve Comparable Outcomes in Non-Squamous Lung Cancer
The comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival.

Targeted Approaches to Certain Lung Cancer Show Promising Results
After chemotherapy disease progresses in some of the patients with advanced BRAF V600E mutant non-small cell lung cancer.